BASDAI Calculator — Bath Ankylosing Spondylitis Disease Activity Index
The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) is a validated patient-reported outcome measure that assesses disease activity in ankylosing spondylitis (AS) and axial spondyloarthritis. It consists of six 10-point visual analogue scale (VAS) questions covering fatigue, spinal pain, peripheral joint pain, enthesitis, and morning stiffness.
About
The BASDAI was developed by Prof. Andrei Calin and colleagues at the Royal National Hospital for Rheumatic Diseases, Bath, UK, and published in 1994. It has become the gold standard outcome measure for assessing disease activity in AS clinical trials and is endorsed by the Assessment of SpondyloArthritis international Society (ASAS) and the Outcome Measures in Rheumatology (OMERACT) initiative. A BASDAI ≥4 is commonly used as a threshold for active disease and eligibility for biologic therapy in many guidelines.
Formula
BASDAI = (Q1 + Q2 + Q3 + Q4 + (Q5 + Q6)/2) / 5
The BASDAI is calculated from six 0-10 VAS questions. Q1: level of fatigue/tiredness. Q2: level of neck, back, or hip pain. Q3: level of joint pain/swelling (peripheral joints). Q4: level of areas tender to touch (enthesitis). Q5: level of morning stiffness severity upon waking. Q6: duration of morning stiffness upon waking (0=0 hours, 10=2+ hours). The average of Q5 and Q6 (morning stiffness) is taken, then added to Q1-Q4, and divided by 5. The final score ranges from 0 (inactive) to 10 (very active). A score ≥4 indicates active disease and is often used as a threshold for biologic therapy eligibility.
Score Interpretation
The BASDAI is the primary outcome measure for disease activity in ankylosing spondylitis clinical trials and is recommended by ASAS/OMERACT. A threshold of BASDAI ≥4 is widely used as an inclusion criterion for biologic therapy trials and clinical eligibility criteria for TNF inhibitors and IL-17 inhibitors. The BASDAI has good construct validity, test-retest reliability (ICC 0.87-0.93), and sensitivity to change. A change of 1 point or more is considered clinically meaningful.
Inactive / Low Disease Activity — 0–3.9
BASDAI <4. Disease activity is controlled. Continue maintenance therapy.
Management: Continue current therapy. Maintain exercise and physical therapy. Monitor every 3-6 months with BASDAI, spinal mobility, and functional assessment.
Active Disease — 4–10
BASDAI ≥4. Active disease requiring treatment escalation.
Management: Escalate therapy. Consider NSAIDs optimization, TNF inhibitors (adalimumab, etanercept, infliximab, golimumab), IL-17 inhibitors (secukinumab, ixekizumab), or JAK inhibitors (tofacitinib, upadacitinib). Assess for extra-articular manifestations.
Reference Ranges
| Population | Normal Range | Notes |
|---|---|---|
| Adults with ankylosing spondylitis / axial spondyloarthritis | 0-10 (≥4 = active disease) | <4: Inactive/low disease activity. ≥4: Active disease (biologic eligibility threshold). |
Dr. Mahmoud El-Sayed
Dr. Mahmoud El-Sayed is a consultant rheumatologist with expertise in spondyloarthritis, inflammatory arthritis, and autoimmune disease management.
View medical review board & editorial policy →Example Calculation
A 32-year-old man with AS: Fatigue=7, Spinal pain=8, Joint pain=3, Enthesitis=6, Stiffness severity=7, Stiffness duration=8 (2+ hours). BASDAI = (7+8+3+6+(7+8)/2)/5 = (24+7.5)/5 = 31.5/5 = 6.3. Active disease (≥4). Recommendation: Escalate therapy, consider TNF inhibitor.
Related Conditions
Related Medications
Common Mistakes
Using BASDAI alone without ASDAS for treatment decisions
While BASDAI ≥4 is commonly used for biologic eligibility, the ASDAS (Ankylosing Spondylitis Disease Activity Score) incorporating CRP provides more objective assessment and better discrimination. Use both BASDAI and ASDAS when available.
Not accounting for patient circadian variation in morning stiffness reporting
Morning stiffness is best assessed when the patient is actively experiencing it. Ideally, the questionnaire should be completed in the morning before significant activity. Patients who complete it in the afternoon or evening may underestimate stiffness duration and severity.
Frequently Asked Questions
What BASDAI score qualifies for biologic therapy in AS?
What is the minimum clinically important difference for BASDAI?
References
- Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286-2291. PubMed
- Zochling J, Braun J. Assessments in ankylosing spondylitis. Best Pract Res Clin Rheumatol. 2006;20(3):521-537.
- Van der Heijde D, Ramiro S, Landew R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978-991. PubMed